Triple-Negative Breast Cancer: An Update on Neoadjuvant Clinical Trials | Zendy

Keith D. Amos | Zendy; Bárbara Adamo | Zendy; Carey K. Anders | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Triple-Negative Breast Cancer: An Update on Neoadjuvant Clinical Trials

Author(s) -

Keith D. Amos,

Bárbara Adamo,

Carey K. Anders

Publication year - 2012

Publication title -

international journal of breast cancer

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.552

H-Index - 15

eISSN - 2090-3170

pISSN - 2090-3189

DOI - 10.1155/2012/385978

Subject(s) - medicine , triple negative breast cancer , breast cancer , neoadjuvant therapy , oncology , malignancy , clinical trial , adjuvant , surrogate endpoint , clinical endpoint , complete response , cancer , adjuvant chemotherapy , chemotherapy

Triple-negative breast cancer (TNBC) is an aggressive malignancy with a poor prognosis despite the high rates of response to chemotherapy. This scenario highlights the need to develop novel therapies and/or treatment strategies to reduce the mortality associated with TNBC. The neoadjuvant setting provides a model for rapid assessment of treatment efficacy with smaller patient accruals and over shorter periods of time compared to the traditional adjuvant setting. In addition, a clear surrogate endpoint of improved survival, known as pathologic complete response, already exists in this setting. Here, we review current data from completed and ongoing neoadjuvant clinical trials for TNBC.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research